Baker Hughes announced the commercial release of its high-performance, low-dosage FATHOM™ XT SUBSEA525 inhibitor that helps control asphaltene deposition in deepwater wells, providing better flow assurance and reducing remediation costs by minimizing the risk of blockages in production lines and equipment. The inhibitor was designed and certified for offshore applications using a proprietary qualification protocol and a stringent laboratory evaluation method to enable full compatibility with subsea equipment and effective performance at low treatment levels.

During production, crude oils can deposit asphaltenes inside pumps and pipes, creating serious production issues such as plugged flow lines and clogged equipment, resulting in the need to stop operations and perform a costly remediation procedure to get production back online at acceptable levels. Many times, these procedures only offer temporary relief. To lessen the risk of asphaltene deposition and enhance flow, the FATHOM XT inhibitor can be applied at low treatment levels during initial production and throughout the life of the well. The low dosage rate simplifies supply logistics, reduces onsite storage and lowers handling risk.

Tags: Baker Hughes Incorporated